Rare disease costs millions to society each year

July 3, 2014 by Claes Keisu

In the first study of its kind, researchers at Karolinska Institutet and Newcastle University in the UK have estimated the economic burden of Duchene muscular dystrophy (DMD) to the public healthcare, affected households and society as a whole. According to research published in the July 2 issue of Neurology, the medical journal of the American Academy of Neurology, a typical DMD-patient annually costs society up to SEK 800,000, resulting in a total burden of SEK 480 million for the DMD population in Sweden.

DMD affects one in 3,500 new-born boys every year. The fatal condition is characterized by progressive muscle weakening caused by a faulty gene. Children with DMD lose their ability to walk independently and become reliant on wheelchairs for mobility usually in their early teens and many patients experience serious respiratory, orthopaedic, and cardiac complications following the aggressive disease development. Life expectancy is around 30 years.

The current study includes 770 patients from Germany, Italy, the UK and the US, who were asked to complete a questionnaire along with their primary caregiver. The results show that the per-patient annual direct cost of illness (SEK 160,000 – 360,000) in all these countries was seven to sixteen times higher than the average health expenditure. The figures include physician visits, clinical tests and assessments, drugs, and medical devices and aids, as well as associated with informal caregiving during leisure time. Other factors, such as due to reduced working hours and reduction in quality of life, were also calculated. Costs borne by each affected household were estimated at between SEK 400,000 and 500,000 annually, including out-of-pockets payments for healthcare services and drugs, loss of income, and reduction in quality of life.

The team behind the findings point out that rare diseases such as DMD often are underfunded, and that the to society are hidden because costs in many countries are carried by the family. Society's reluctance to invest in the development of treatments, clinics and specialist healthcare for people with DMD is another problem, according to the researchers.

Explore further: 'Skipping' drug marks step forward for muscular dystrophy

More information: "The Burden of Duchenne Muscular Dystrophy: An International, Cross-Sectional Study", Erik Landfeldt, Peter Lindgren, Christopher F. Bell, Claude Schmitt, Michela Guglieri, Volker Straub, Hanns Lochmüller, Katharine Bushby. Neurology online July 2, 2014, DOI: 10.1212/WNL.0000000000000669

Related Stories

Treating Duchenne muscular dystrophy

December 2, 2013

(Medical Xpress)—Reviving a gene which is 'turned down' after birth could be the key to treating Duchenne muscular dystrophy (DMD), an incurable muscle-wasting condition that affects one in every 3,500 boys.

Recommended for you

Special nerve cells cause goose bumps and nipple erection

August 29, 2016

The sympathetic nerve system has long been thought to respond the same regardless of the physical or emotional stimulus triggering it. However, in a new study from Karolinska Institutet published in the Nature Neuroscience, ...

A new window to understanding the brain

August 29, 2016

Scientists in recent years have made great strides in the quest to understand the brain by using implanted probes to explore how specific neural circuits work.

Next steps in understanding brain function

August 26, 2016

The most complex piece of matter in the known universe is the brain. Neuroscientists have recently taken on the challenge to understand brain function from its intricate anatomy and structure. There is no sure way to go about ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.